STAT3
Overview
STAT3 is a JAK/STAT pathway transcription factor recurrently altered in peripheral T-cell lymphoma.
Alterations observed in the corpus
- STAT3 was among recurrently altered genes profiled in subset analyses of nodal peripheral T-cell lymphoma treated with CHOP-based chemotherapy PMID:37078708.
- WES of 55 DLBCL tumors identified recurrent STAT3 mutations, highlighting constitutive JAK-STAT pathway activation as a driver mechanism in diffuse large B-cell lymphoma PMID:22343534
- Downstream of IL-6 inflammatory signaling and of FXR–SHP repression in cholangiocarcinoma; loss of FXR activity unleashes STAT3 phosphorylation and BCL2L1 (Bcl-xL)-mediated survival PMID:25608663
- Activating p.Tyr640Phe mutation in two mycosis fungoides cases; JAK3/STAT3/SH2B3 genotype supports stratification for JAK-pathway inhibitor trials (tofacitinib, ruxolitinib) PMID:26551667
- Flagged within MRT-specific super-enhancers; prior roles in stem-cell self-renewal and differentiation suggest dependency in extra-cranial MRT PMID:26977886
Cancer types (linked)
- PTCL — recurrently altered in subset analyses PMID:37078708.
Co-occurrence and mutual exclusivity
- Not reported in the corpus.
Therapeutic relevance
- No direct targeted therapy reported in the corpus.
Open questions
- Independent prognostic effect not established in the PTCL cohort PMID:37078708.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:22343534
This page was processed by crosslinker on 2026-05-14. - PMID:25608663
This page was processed by crosslinker on 2026-05-14. - PMID:26551667
This page was processed by crosslinker on 2026-05-14. - PMID:26977886
This page was processed by wiki-cli on 2026-05-14.